Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Seelos Therapeutics, Inc. - Common Stock (NQ: SEEL )

1.280 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seelos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Drug Developer Mindset Pharma Optimistic About 2023 After Key 2022 Funding Collaborations And Patent Allowances
Once considered the realm of ancient civilizations and countercultures, psychedelics have in the past few years been seeing increasing interest.  
Via Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2023
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
A "Multi-Bagger" Portfolio For 2023 - Introduction
I am optimistic that the market will perform better in 2023 so I've put together a basket of 10 stocks that could well realize multi-bagger returns this year. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From January 11, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 10, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 9, 2023
Via Benzinga
ATAI Life Sciences, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 5, 2023
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 2, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From December 29, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 28, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 27, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From January 3, 2023
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 30, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 26, 2022
Via Benzinga
Largest Psychedelic Stocks -7.6% This Week; Now -21.7% This Month
Highlighting the performance of the six stocks in our Psychedelic Drug Stocks Index, which are researching the treatment of mental illnesses using 10 different psychedelic substances. 
Via Talk Markets
Cannabis Category Performances Ranged From +0.5% To -17% Last Week
The 5 categories in the cannabis sector perform quite differently week-to-week and last week was no exception. Below is a summary of each category's performance last week, in descending order, since... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 23, 2022
Via Benzinga
Cybin, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 21, 2022
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 19, 2022
Via Benzinga
Major Psychedelic Drug Stocks Down Another 7% This Week; Now Down 54% YTD
The 6 largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances are down again this week. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.